Related Experiment Video

Updated: Mar 21, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies

Chun-Hsiang Wang1, Yuchi Hwang2, Eugene Lin2

  • 1Department of Hepatogastroenterology, Tainan Municipal Hospital, Tainan, Taiwan.

Journal of Experimental Pharmacology
|May 18, 2016
PubMed

Insights

Pharmacogenomics can predict treatment response in chronic hepatitis C (CHC) patients receiving interferon (IFN) therapy. Genetic variations, particularly in the interleukin 28B gene, are key to understanding individual responses to CHC treatment.

Area of Science:

  • Pharmacogenomics
  • Hepatology
  • Immunogenetics

Background:

  • Chronic hepatitis C (CHC) is a persistent liver disease caused by the hepatitis C virus (HCV).
  • Current pegylated interferon (peg-IFN) and ribavirin (RBV) treatments for CHC face challenges due to high costs and adverse effects.
  • Identifying predictors of treatment response is crucial for clinical and economic reasons.

Purpose of the Study:

  • To review current data on the pharmacogenomics of interferon (IFN) efficacy in CHC patients.
  • To explore the role of genetic variations in predicting treatment outcomes.
  • To highlight the potential for personalized medicine in CHC treatment.

Main Methods:

  • Review of recent scientific literature on pharmacogenomics and CHC treatment.
  • Examination of single nucleotide polymorphisms (SNPs) as genetic markers.
  • Discussion of genome-wide association studies (GWAS) and candidate-gene approaches.

Main Results:

  • Single nucleotide polymorphisms (SNPs) are associated with the therapeutic response to IFN in CHC.
  • Specific SNPs within the interleukin 28B gene show a strong correlation with IFN responsiveness.
  • Genome-wide association studies (GWAS) are effective in identifying these genetic determinants.

Conclusions:

  • Pharmacogenomic approaches, particularly GWAS, can identify genetic factors influencing IFN treatment response in CHC.
  • Interleukin 28B gene polymorphisms are significant predictors of treatment outcomes.
  • These findings support the development of individualized medicine strategies for CHC patients.

Keywords:
chronic hepatitis Cgenome-wide association studyinterferonpharmacogenomicsribavirinsingle nucleotide polymorphisms

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.1K
Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization08:27

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

4.9K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
101
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
108
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
135
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
102
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.5K